Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Red Blood Cells from COVID-19 Patients Show Evidence of Increased Oxidative Stress and Increased Lactate Influx

Philip Murphy, Edel Mullen, Stephen Bergin, Geraldine Healy, Michelle Lavin, John Quinn, Siobhan Glavey

Blood (2021) 138 (Supplement 1): 928.

https://doi.org/10.1182/blood-2021-146305

Published: 2021

Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy

Blood (2021) 138 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2021-145530

Published: 2021

Journal Articles

Primary Myeloma Cell Induced Von Willebrand Factor Release from the Endothelium Is Mediated By VEGF and Attenuated By Heparin

Claire Comerford, Sukhraj Pal Singh Dhami, Philip Murphy, Sean Patmore, Siobhan Glavey, John Quinn, Jamie M. O'Sullivan

Blood (2021) 138 (Supplement 1): 3141.

https://doi.org/10.1182/blood-2021-149134

Published: 2021

Journal Articles

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Mohamed Bakri Mohamed, Seán R Millar, Vitaliy Mykytiv, Rose McMorrow, Conan Donnelly, Paul M Walsh, Eamonn O'Leary, Nina Orfali, Philip Murphy, Paul V. Browne, John Quinn, Peter O'Gorman, Ruth Clifford, Ezzat El Hassadi, Oonagh Gilligan, Janusz Krawczyk, Michael E. O'Dwyer, Eva Szegezdi, Mary R Cahill

Blood (2021) 138 (Supplement 1): 1218.

https://doi.org/10.1182/blood-2021-149832

Published: 2021

Journal Articles

Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma

Lyndsey Flanagan, Michael E. O'Dwyer, Philip Murphy, John Quinn, Siobhan Glavey, Triona Ni Chonghaile

Blood (2021) 138 (Supplement 1): 4703.

https://doi.org/10.1182/blood-2021-147185

Published: 2021

Journal Articles

Non Double-Hit Diffuse Large B Cell Lymphoma Treated with R-CHOP Has Excellent Overall Survival If Interim Scan Shows Partial or Complete Response

Philip Murphy, MD, Siobhan Glavey, MDPhD, Oscar Breathnach, MD, Philip W Murphy, Liam Grogan, MD, Patrick Morris, MD, John Quinn, MB,PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-138402

Published: 2020

Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2018-99-112375

Published: 2018

Journal Articles

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Saad Ahmed, MBBS, Mattia Cremona, PhD, Sinead Toomey, PhD, Mark Catherwood, PhD, Stephen Bergin, BS, Paul Kennedy, BS, Bryan Hennessy, MD, Patrick Thornton, MB, FRCPath, John Quinn, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 5532.

https://doi.org/10.1182/blood-2018-99-114104

Published: 2018

Journal Articles

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Aisling Barrett, John Quinn, MD PhD, Siobhan Glavey, MD PhD, Jeremy Sargent, FRCPath, Michelle Lavin, MB, PhD FRCPath, Patrick Thornton, MB, FRCPath, James S O'Donnell, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 1223.

https://doi.org/10.1182/blood-2018-99-116148

Published: 2018

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

Journal Articles

From a DOAC to Warfarin: Reasons Why Patients Switch

Aisling Barrett, MB, BCh, BAO, MRCPI, Sahar Khan, MRCPI, Margaret Moore, RGN, Patricia Ferrins, RGN, BSc, Jeremy Sargent, FRCPath, Patrick Thornton, Philip Murphy, John Quinn

Blood (2017) 130 (Supplement 1): 4910.

https://doi.org/10.1182/blood.V130.Suppl_1.4910.4910

Published: 2017

Journal Articles

Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations

Saad Ahmed, MBBS, MRCP, John Quinn, Mark Catherwood, Patrick Thornton, Stephen Bergin, Paul Kennedy, Sally Elsir, Bryan Hennessy, Philip Murphy

Blood (2017) 130 (Supplement 1): 5323.

https://doi.org/10.1182/blood.V130.Suppl_1.5323.5323

Published: 2017

Journal Articles

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Cian McEllistrim, MD, Mary R Cahill, MD, Philip Murphy, PhD BPharm, Vitaliy Mykytiv, MD, John Quinn, Amanda Bray, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Grace Hirakata, Imelda Parker, Andres Hernando, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 3163.

https://doi.org/10.1182/blood.V130.Suppl_1.3163.3163

Published: 2017

Journal Articles

Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma

Charalampia Kyriakou, MD PhD, Philip Murphy, MD, Maria Teresa Petrucci, MD, Pamela Bacon, Philip Lewis, Hélène Gilet, MSc, Benoit Arnould, PhD, Isabelle Vande Broek, MD PhD, Xavier Leleu, MD

Blood (2015) 126 (23): 2085.

https://doi.org/10.1182/blood.V126.23.2085.2085

Published: 2015

Journal Articles

The Retinoid Derivative Drug, Acitretin, Modulates CD38 Expression on MEC-1 Cells and Primary Chronic Lymphocytic Leukemia (CLL) Cells and Reduces Migration in Response to the Chemokine CXCL12

Sally Elsir Mohammed, MBBS, MRCP(UK), Philip Murphy, MD, John Quinn, Patrick Thornton, FRCPath, Stephen Bergin, Bryan Hennessy

Blood (2015) 126 (23): 5271.

https://doi.org/10.1182/blood.V126.23.5271.5271

Published: 2015

Journal Articles

Multicentre Retrospective Analysis of Rituximab Use in the Treatment of Steroid Resistant Autoimmune Haemolytic Anaemia in Ireland,

Su Wai Maung, MBBS, MRCP(UK), Denis O'Keeffe, MD, MRCPath, Maeve Leahy, MD, MRCPath, Hilary M O'Leary, MBBChBAO, MRCPI, MRCPath, Irfan Khan, Mary Cahill, FRCPath, Oonagh Galligan, FRCPath, Philip Murphy, MD, MRCPath, Janusz Krawczyk, MRCPI, Suzanne McPherson, MRCPI, J F Jackson, FRCPath, Mary Ryan, FRCPath, Brian Hennessy, MRCPath, Aine C Burke, MBBChBAO, MRCPI, Helen Enright, MD, Johnny McHugh, FRCPath

Blood (2011) 118 (21): 3171.

https://doi.org/10.1182/blood.V118.21.3171.3171

Published: 2011

Journal Articles

A Panel of POTENTIAL PROTEIN BIOMARKERS for Predicting CLINICAL RESPONSE to Thalidomide IN Newly Diagnosed MULTIPLE MYELOMA PATIENTS.

Rajesh Rajpal, Paul Dowling, Justine Meiller, William G Murphy, Kenneth C. Anderson, MD, Philip Murphy, Robert O Connor, Martin Clynes, Peter O'Gorman, M.D.

Blood (2009) 114 (22): 4882.

https://doi.org/10.1182/blood.V114.22.4882.4882

Published: 2009

Journal Articles

Prediction of Thalidomide Response in the Newly Diagnosed Untreated Multiple Myeloma Patients Based on a Panel of Protein Biomarkers

Rajpal Rajpal, Paul Dowling, Justine Meiller, Kenneth C Anderson, MD, Philip Murphy, Martin Clynes, Peter O’Gorman

Blood (2008) 112 (11): 5018.

https://doi.org/10.1182/blood.V112.11.5018.5018

Published: 2008

Journal Articles

Hypereosinophilic Syndromes (HES)-Variable Presentation and Response to Current Treatment Options: Absence of the FIP1L1-PDGFRa Fusion Gene Does Not Exclude Imatinib as a Treatment Option.

Subir Mitra, Philip Murphy, Patrick Thornton, Mary Mccloy

Blood (2006) 108 (11): 4922.

https://doi.org/10.1182/blood.V108.11.4922.4922

Published: 2006

NARROW

Red Blood Cells from COVID-19 Patients Show Evidence of Increased Oxidative Stress and Increased Lactate Influx

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Primary Myeloma Cell Induced Von Willebrand Factor Release from the Endothelium Is Mediated By VEGF and Attenuated By Heparin

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma

Non Double-Hit Diffuse Large B Cell Lymphoma Treated with R-CHOP Has Excellent Overall Survival If Interim Scan Shows Partial or Complete Response

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

From a DOAC to Warfarin: Reasons Why Patients Switch

Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma

The Retinoid Derivative Drug, Acitretin, Modulates CD38 Expression on MEC-1 Cells and Primary Chronic Lymphocytic Leukemia (CLL) Cells and Reduces Migration in Response to the Chemokine CXCL12

Multicentre Retrospective Analysis of Rituximab Use in the Treatment of Steroid Resistant Autoimmune Haemolytic Anaemia in Ireland,

A Panel of POTENTIAL PROTEIN BIOMARKERS for Predicting CLINICAL RESPONSE to Thalidomide IN Newly Diagnosed MULTIPLE MYELOMA PATIENTS.

Prediction of Thalidomide Response in the Newly Diagnosed Untreated Multiple Myeloma Patients Based on a Panel of Protein Biomarkers

Hypereosinophilic Syndromes (HES)-Variable Presentation and Response to Current Treatment Options: Absence of the FIP1L1-PDGFRa Fusion Gene Does Not Exclude Imatinib as a Treatment Option.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only